Application site tingling

Verify with FDA CVM →

VeDDRA Code: 2193

60 adverse event reports referencing this reaction

60
Total Reports
0
Deaths
0.0%
Death Rate

Species Most Affected

Human 60

Breeds Most Affected

Unknown 60

Associated Drugs

Fluralaner Spot-On Solution 23
Imidacloprid + Moxidectin 14
Selamectin 7
Fluralaner/Moxidectin Spot-On 6
Unspecified Hand Soap 2
Emodepside + Praziquantel 1
Miconazole Nitrate + Polymyxin B Sulfate + Prednisolone Acetate 1
Mercaptobenzothiazole 1
Tildipirosin Injectable 1
Dexmedetomidine Hydrochloride 1
Unknown Soap 1
Dimethyl Sulfoxide; Fluocinolone Acetonide 1
Unspecified Liquid Dish Soap 1
Soap 1
Enrofloxacin 1
Fluocinolone Acetonide And Dimethyl Sulfoxide 1
Mirtazapine 1
Montelukast 1
Fexofenadine 1
Mesalamine 1

Data Summary

Metric Value
Total reports referencing reaction 60
Reports with fatal outcome 0
Case-fatality rate (reported events) 0.0%
Species observed 1
Breeds observed 1
Drugs associated with reaction 20

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER); reaction term coded under VeDDRA 2193.

Application site tingling Reaction Insights

The FDA Center for Veterinary Medicine database currently lists 60 adverse event reports that reference Application site tingling as a reaction term, including 0 reports with a death outcome — a 0.0% case-fatality figure calculated across only those events where this reaction was coded. The reaction is indexed in the openFDA system under VeDDRA code 2193, the standardized veterinary dictionary used to normalize clinical signs across submitters. Because reports are voluntary and often describe multiple concurrent signs per animal, the volume here reflects reporting intensity rather than true incidence in the broader pet population.

Application site tingling appears most frequently in reports for Human (60 reports) — with Human dominating at 60 entries. Within those species, the breeds most often named alongside this reaction are Unknown (60). These distributions are influenced both by underlying breed popularity and by how veterinarians and owners code a given clinical sign, so they should be interpreted as a reporting fingerprint rather than a pure susceptibility ranking.

The drugs most commonly co-reported with Application site tingling are Fluralaner Spot-On Solution (23 reports), Imidacloprid + Moxidectin (14 reports), Selamectin (7 reports), Fluralaner/Moxidectin Spot-On (6 reports), with Fluralaner Spot-On Solution appearing alongside this reaction in 23 submissions. Co-reporting does not establish that any specific product caused the reaction — FDA CVM data captures temporal association only. The value of these aggregates is in flagging which therapeutic classes appear repeatedly alongside a given clinical sign, so owners and veterinarians can ask targeted questions about medications currently in use.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial